Q4 EPS Estimate for Kezar Life Sciences Decreased by Analyst

Kezar Life Sciences, Inc. (NASDAQ:KZR - Free Report) - Investment analysts at HC Wainwright dropped their Q4 2024 earnings per share (EPS) estimates for shares of Kezar Life Sciences in a report issued on Monday, December 2nd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($2.59) per share for the quarter, down from their prior forecast of ($1.70). HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for Kezar Life Sciences' current full-year earnings is ($6.30) per share. HC Wainwright also issued estimates for Kezar Life Sciences' Q1 2025 earnings at ($2.56) EPS, Q2 2025 earnings at ($2.57) EPS, Q3 2025 earnings at ($2.59) EPS, Q4 2025 earnings at ($2.61) EPS and FY2025 earnings at ($10.33) EPS.

Kezar Life Sciences (NASDAQ:KZR - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($2.78) EPS for the quarter, topping the consensus estimate of ($3.03) by $0.25.

A number of other equities analysts have also commented on KZR. William Blair reaffirmed a "market perform" rating on shares of Kezar Life Sciences in a report on Wednesday, November 13th. Wells Fargo & Company cut their price target on Kezar Life Sciences from $20.00 to $11.00 and set an "equal weight" rating for the company in a report on Thursday, November 14th.

Kezar Life Sciences Stock Performance

NASDAQ KZR traded down $0.02 on Wednesday, hitting $7.05. 46,657 shares of the stock traded hands, compared to its average volume of 73,860. The business's fifty day moving average is $7.61 and its two-hundred day moving average is $6.77. Kezar Life Sciences has a 12 month low of $5.20 and a 12 month high of $11.35. The firm has a market capitalization of $51.47 million, a price-to-earnings ratio of -0.53 and a beta of 0.25. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.65 and a current ratio of 7.65.

Institutional Investors Weigh In On Kezar Life Sciences

A number of large investors have recently added to or reduced their stakes in KZR. Vanguard Group Inc. raised its position in Kezar Life Sciences by 1.0% during the first quarter. Vanguard Group Inc. now owns 3,094,224 shares of the company's stock valued at $2,790,000 after purchasing an additional 30,740 shares in the last quarter. Acuitas Investments LLC increased its holdings in shares of Kezar Life Sciences by 42.8% in the second quarter. Acuitas Investments LLC now owns 986,785 shares of the company's stock worth $592,000 after buying an additional 295,956 shares during the period. Acadian Asset Management LLC increased its holdings in shares of Kezar Life Sciences by 3.6% in the second quarter. Acadian Asset Management LLC now owns 1,855,194 shares of the company's stock worth $1,112,000 after buying an additional 64,356 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Kezar Life Sciences in the second quarter worth about $63,000. Finally, Mackenzie Financial Corp purchased a new position in shares of Kezar Life Sciences in the second quarter worth about $35,000. Hedge funds and other institutional investors own 67.90% of the company's stock.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.